{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:19:47Z","timestamp":1791062387146,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.crohns.2011.12.003","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T06:46:07Z","timestamp":1326264367000},"page":"698-707","source":"Crossref","is-referenced-by-count":65,"title":["Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy"],"prefix":"10.1093","volume":"6","author":[{"given":"Lennard P.L.","family":"Gilissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis R.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopold G.J.B.","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rgen","family":"Bierau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap A.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9e D.C.","family":"Paulussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle J.","family":"Romberg-Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Stronkhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens P.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet M.","family":"Hooymans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold W.","family":"Stockbr\u00fcgger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"Neef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad A.M.","family":"Masclee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"issue":"2","key":"10.1016\/j.crohns.2011.12.003_bb0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/138161210790112773","article-title":"Pharmacogenetics of thiopurines in inflammatory bowel disease","volume":"16","author":"Derijks","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10.1016\/j.crohns.2011.12.003_bb0010","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.crohns.2011.12.003_bb0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000028394","article-title":"Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance","volume":"61","author":"Krynetski","year":"2000","journal-title":"Pharmacology"},{"issue":"2","key":"10.1016\/j.crohns.2011.12.003_bb0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/gut.51.2.143","article-title":"TPMT in the treatment of Crohn's disease with azathioprine","volume":"51","author":"Lennard","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2011.12.003_bb0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.crohns.2011.12.003_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007691-200406000-00016","article-title":"Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease; implications for therapy","volume":"26","author":"Derijks","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.crohns.2011.12.003_bb0035","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.dld.2004.09.029","article-title":"Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations","volume":"37","author":"Al Hadithy","year":"2005","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.crohns.2011.12.003_bb0040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/gut.39.3.401","article-title":"6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity","volume":"39","author":"Cuffari","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2011.12.003_bb0045","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":"6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.12.003_bb0050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/gut.48.5.591","article-title":"Rational dosing of azathioprine and 6-mercaptopurine","volume":"48","author":"Sandborn","year":"2001","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.crohns.2011.12.003_bb0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00054725-200407000-00003","article-title":"Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease","volume":"10","author":"Achkar","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.crohns.2011.12.003_bb0060","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/j.1572-0241.2004.30415.x","article-title":"The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease","volume":"99","author":"Goldenberg","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.crohns.2011.12.003_bb0065","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/00365520410007980","article-title":"Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease","volume":"39","author":"Hindorf","year":"2004","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"10.1016\/j.crohns.2011.12.003_bb0070","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/gut.2003.032896","article-title":"Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease","volume":"53","author":"Wright","year":"2004","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.crohns.2011.12.003_bb0075","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/gut.48.5.642","article-title":"Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease","volume":"48","author":"Cuffari","year":"2001","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.crohns.2011.12.003_bb0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00365520150218084","article-title":"Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease","volume":"36","author":"Belaiche","year":"2001","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.crohns.2011.12.003_bb0085","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.49.5.665","article-title":"Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease","volume":"49","author":"Lowry","year":"2001","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.crohns.2011.12.003_bb0090","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00005176-200110000-00006","article-title":"6-mercaptopurine metabolite levels in children with inflammatory bowel disease","volume":"33","author":"Gupta","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2011.12.003_bb0095","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","article-title":"Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis","volume":"130","author":"Osterman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.12.003_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1572-0241.2007.01511.x","article-title":"Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism","volume":"102","author":"De Boer","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2011.12.003_bb0105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1365-2036.2003.01778.x","article-title":"Drug interaction between infliximab and azathioprine in patients with Crohn's disease","volume":"18","author":"Roblin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"26","key":"10.1016\/j.crohns.2011.12.003_bb0110","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.crohns.2011.12.003_bb0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0378-4347(92)80347-S","article-title":"High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample","volume":"583","author":"Lennard","year":"1992","journal-title":"J Chromatogr"},{"issue":"1","key":"10.1016\/j.crohns.2011.12.003_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1994.tb04314.x","article-title":"Thiopurine methyltransferase activity in a French population: HPLC assay conditions and effects of drugs and inhibitors","volume":"38","author":"Jacques-Aigrain","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.crohns.2011.12.003_bb0125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00044011-200424080-00006","article-title":"Therapeutic drug monitoring in 15 patients with inflammatory bowel disease and established azathioprine therapy","volume":"24","author":"Gilissen","year":"2004","journal-title":"Clin Drug Investig"},{"issue":"10","key":"10.1016\/j.crohns.2011.12.003_bb0130","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.2001.04683.x","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume":"96","author":"Kane","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.crohns.2011.12.003_bb0135","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1572-0241.2003.07522.x","article-title":"Patient nonadherence to medication in inflammatory bowel disease","volume":"98","author":"Sewitch","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.crohns.2011.12.003_bb0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcome of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.crohns.2011.12.003_bb0145","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/FTD.0b013e31815bf4dc","article-title":"The role of xanthine oxidase in thiopurine metabolism: a case report","volume":"29","author":"Wong","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.crohns.2011.12.003_bb0155","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.dld.2006.05.026","article-title":"Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease","volume":"39","author":"Gilissen","year":"2007","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.crohns.2011.12.003_bb0160","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1046\/j.1365-2036.2002.01353.x","article-title":"Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease","volume":"16","author":"Ansari","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.crohns.2011.12.003_bb0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2036.2002.01177.x","article-title":"Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine","volume":"16","author":"Campbell","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.crohns.2011.12.003_bb0170","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00004836-200209000-00008","article-title":"Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease","volume":"35","author":"Regueiro","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2011.12.003_bb0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.dld.2008.01.003","article-title":"Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease","volume":"40","author":"Kwan","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.crohns.2011.12.003_bb0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","article-title":"Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis","volume":"123","author":"Pearson","year":"1995","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.crohns.2011.12.003_bb0185","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/gut.52.1.140","article-title":"Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine","volume":"52","author":"Kaskas","year":"2003","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.crohns.2011.12.003_bb0190","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2006.02.045","article-title":"When is too much enough?","volume":"130","author":"Mayer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2011.12.003_bb0195","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1373\/clinchem.2007.086215","article-title":"6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial","volume":"53","author":"Reinshagen","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.crohns.2011.12.003_bb0210","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2036.2011.04756.x","article-title":"Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients","volume":"34","author":"Gonz\u00e1lez-Lama","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.crohns.2011.12.003_bb0215","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.crohns.2011.12.003_bb0220","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/ibd.21190","article-title":"Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide","volume":"16","author":"Hanai","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.crohns.2011.12.003_bb0225","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/ibd.21458","article-title":"Clinical usefulness of therapeutic drug monitoring in patients with inadequately controlled inflammatory bowel disease","volume":"17","author":"Haines","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.crohns.2011.12.003_bb0230","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1002\/ibd.21662","article-title":"Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts","volume":"17","author":"Roblin","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2011.12.003_bb0235","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.dld.2010.09.001","article-title":"Thiopurine Task Force Interest Group. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease\u2014proceedings of the first Thiopurine Task Force meeting","volume":"43","author":"Van Asseldonk","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.crohns.2011.12.003_bb0240","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1365-2036.2011.04814.x","article-title":"Thiopurine metabolite measurement \u2014 not for everyone","volume":"34","author":"Van Asseldonk","year":"2011","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994611003400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994611003400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/6\/6\/698\/1083977\/6-6-698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T20:08:01Z","timestamp":1503432481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2011.12.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1873994611003400"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2011.12.003","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}